Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer (Q36163935)

12 August 2017

Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer (English)

1 reference

12 August 2017

1 reference

1 reference

1 reference

1 reference

Junya Zhu

1

1 reference

12 August 2017

Dhruv B Sharma

2

1 reference

12 August 2017

Stacy W Gray

3

1 reference

12 August 2017

Aileen B Chen

4

1 reference

12 August 2017

Jane C Weeks

5

1 reference

12 August 2017

Deborah Schrag

6

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 2012

1 reference

The Journal of the American Medical Association

12 August 2017

1 reference

12 August 2017

307

1 reference

12 August 2017

15

1 reference

12 August 2017

1593-1601

1 reference

Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Treatment of advanced non-small-cell lung cancer in the elderly

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Utility of the SEER-Medicare data to identify chemotherapy use.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Development of a comorbidity index using physician claims data

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Marginal structural models and causal inference in epidemiology

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Estimating causal effects from large data sets using propensity scores

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418968

Does reimbursement influence chemotherapy treatment for cancer patients?

23 September 2018

1 reference

12 December 2020

Estimating treatment effects using observational data

1 reference

12 December 2020

Treatment of advanced non small-cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies

1 reference

12 December 2020

Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Targeted therapies take aim against lung cancer and melanoma

1 reference

12 December 2020

Staging strategies for lung cancer

1 reference

12 December 2020

A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer

1 reference

12 December 2020

Identifiers

DOI

10.1001/JAMA.2012.454

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22511687

1 reference